TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26102257

Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration (WBV) training, twice a week for 8 months
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no change in habitual lifestyle)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration (WBV) training
Number of subjects: 37
Study: 24858163

Group type: EXPERIMENTAL
Intervention: Peginterferon α‐2a 180μg once weekly plus ribavirin daily for 24 weeks (genotypes 2 and 3) or 48 weeks (genotypes 1 and 4)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Peginterferon α‐2a plus ribavirin
Number of subjects: 64
Study: 23021898

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Nicotine challenge
Number of subjects: 44
Study: 19641272

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg once daily for 14 days
Number of subjects: 570

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 570
Study: 17584571

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 120

Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 120
Study: 16280696

Group type: EXPERIMENTAL
Intervention: EPZ administered once daily
Number of subjects: 260

Group type: COMPARATOR
Intervention: ABC + 3TC administered twice daily
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 260
Study: 11897728

Group type: COMPARATOR
Intervention: Usual-care counseling from a pharmacist
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Longer adherence counseling session and follow-up phone call from the pharmacist
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Both groups (Usual-care and Longer counseling)
Number of subjects: 333
Study: 10534590

Group type: EXPERIMENTAL
Intervention: Percutaneous electrical nerve stimulation (PENS)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sham-PENS
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: PENS
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 64
Study: 7785758

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 1044

Group type: COMPARATOR
Intervention: Metoclopramide 10 mg
Number of subjects: 1044

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1044
Study: 2139338

Group type: EXPERIMENTAL
Intervention: GR32191B (80 mg; p.o.)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: GR32191B (40 mg; p.o.)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Glyceryl trinitrate (1 mg sub-lingually)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 369682

Group type: EXPERIMENTAL
Intervention: FAC (5‐fluorouracil, adriamycin, and cyclophosphamide)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: FAI (5‐fluorouracil, adriamycin, and ifosfamide)
Number of subjects: 166
Study: 30951686

Group type: EXPERIMENTAL
Intervention: Half-dose photodynamic therapy (PDT)
Number of subjects: 156

Group type: COMPARATOR
Intervention: High-density subthreshold micropulse laser (HSML)
Number of subjects: 156
Study: 28221062

Group type: EXPERIMENTAL
Intervention: Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure
Number of subjects: 54
Study: 24562315

Group type: EXPERIMENTAL
Intervention: Single-Incision Transumbilical Surgery (SITUS)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Conventional Laparoscopy (CLS)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Single-Port Laparoscopic Surgery (SPLS)
Number of subjects: 63
Study: 23829679

Group type: EXPERIMENTAL
Intervention: Fragranced aerosol exposure (15 and 30 minutes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo aerosol exposure (15 and 30 minutes)
Number of subjects: 0
Study: 21752262

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 80 ppm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19770281

Group type: EXPERIMENTAL
Intervention: Combination treatment with S/pre‐S1/pre‐S2 vaccine and lamivudine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Lamivudine monotherapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Vaccine monotherapy
Number of subjects: 120
Study: 16714768

Group type: EXPERIMENTAL
Intervention: Pulmonary-artery catheter (PAC)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Central venous catheter (CVC)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: PAC
Number of subjects: 1000

Group type: COMPARATOR
Intervention: CVC
Number of subjects: 1000
Study: 15578399

Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg po b.i.d. for 30 days
Number of subjects: 146

Group type: COMPARATOR
Intervention: Doxycycline 100 mg po b.i.d. for 45 days
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Doxycycline treatment for 45 days
Number of subjects: 146
Study: 11149482

Group type: EXPERIMENTAL
Intervention: Strength training (S)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Fitness training (F)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Nonexercise control (C)
Number of subjects: 126
Study: 9510680

Group type: EXPERIMENTAL
Intervention: Long-stretch bandage (Setopress)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Short-stretch bandage (Elastocrepe)
Number of subjects: 32
Study: 8044602

Group type: EXPERIMENTAL
Intervention: tranexamic acid 1 g three times daily
Number of subjects: 160

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 160
Study: 2508501

Group type: EXPERIMENTAL
Intervention: Metrifonate (MT, 10 mg/kg body weight)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Praziquantel (PR, 40 mg/kg body weight)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 312
Study: 1062357

Group type: EXPERIMENTAL
Intervention: Fructose (F)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Xylitol (X)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Sucrose (S)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Xylitol (X) in chewing gum
Number of subjects: 125

Group type: COMPARATOR
Intervention: Sucrose (S) in chewing gum
Number of subjects: 125
Study: 31273511

Group type: EXPERIMENTAL
Intervention: HAI raltitrexed (3 mg/m2 over 1 h) followed by oxaliplatin (130 mg/m2 over 2 h) every 3 weeks
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 57
Study: 27552929

Group type: EXPERIMENTAL
Intervention: Plasma of argon (G2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (G1)
Number of subjects: 30
Study: 25499925

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (ZESs)
Number of subjects: 2332

Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SESs)
Number of subjects: 2332
Study: 22325728

Group type: EXPERIMENTAL
Intervention: Foam
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Gel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hand Wipe
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (untreated finger pads)
Number of subjects: 30
Study: 21047395

Group type: EXPERIMENTAL
Intervention: Olanzapine (5 to 20 mg/day) for 24 to 28 weeks
Number of subjects: 980
Study: 19281092

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg once daily
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study: 16202527

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (25 units per trigger point)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Bupivacaine (0.5 ml of 0.5% per trigger point)
Number of subjects: 18
Study: 12063948

Group type: EXPERIMENTAL
Intervention: Bipolar scissors (group BS)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Conventional method (group CM)
Number of subjects: 53
Study: 10327086

Group type: EXPERIMENTAL
Intervention: Ergonomic modifications to tasks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Before ergonomic modifications
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: After ergonomic modifications
Number of subjects: 20
Study: 1723323

Group type: EXPERIMENTAL
Intervention: 40 mg propranolol
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 6280600

Group type: EXPERIMENTAL
Intervention: Cefotaxime (1-g dose)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 39
Study: 31326438

Group type: EXPERIMENTAL
Intervention: Hungry group detecting high-fat food
Number of subjects: 0

Group type: COMPARATOR
Intervention: Satiated group detecting high-fat food
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hungry group detecting food targets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Satiated group detecting food targets
Number of subjects: 0
Study: 28186251

Group type: EXPERIMENTAL
Intervention: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (single-tablet regimen)
Number of subjects: 151
Study: 25658240

Group type: EXPERIMENTAL
Intervention: Black tea (129 mg flavonoids)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 25799800

Group type: EXPERIMENTAL
Intervention: Topical steroid (Mometasone furoate 0.1% cream) and Topical placental extract gel
Number of subjects: 100

Group type: COMPARATOR
Intervention: Topical steroid (Mometasone furoate 0.1% cream) and Topical Tacrolimus 0.1% cream
Number of subjects: 100
Study: 22736463

Group type: EXPERIMENTAL
Intervention: Supersaturated calcium phosphate rinse (SCPR) four times daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Customary care (topical mouth solutions made with salvia leaf extract, iodine-povidine, and fluconazole)
Number of subjects: 40
Study: 17559743

Group type: EXPERIMENTAL
Intervention: Olopatadine 0.2%
Number of subjects: 92

Group type: COMPARATOR
Intervention: Epinastine 0.05%
Number of subjects: 92
Study: 17006401

Group type: EXPERIMENTAL
Intervention: Low-dose oral contraceptive (LD-OC) pill
Number of subjects: 917

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 917
Study: 12813191

Group type: EXPERIMENTAL
Intervention: Planar scintigraphy (20% threshold) in 51 patients
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: SPECT (30% and 35% threshold) in 40 patients
Number of subjects: 91

Group type: COMPARATOR
Intervention: Ultrasonography
Number of subjects: 91
Study: 11112975

Group type: EXPERIMENTAL
Intervention: Cochlear Implant (CI) users
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (deaf candidates on the waiting list for CIs)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Nijmegen Cochlear Implantation Questionnaire (NCIQ)
Number of subjects: 91
Study: 8806347

Group type: EXPERIMENTAL
Intervention: High-Density Lipoprotein Intervention
Number of subjects: 2531
Study: 1320440

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 6370980

Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 31790749

Group type: EXPERIMENTAL
Intervention: Fasted-refed group (fasted for 30 days and then fed to satiation for 30 days)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (fed until satiation for 60 days)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fasted-refed group
Number of subjects: 120
Study: 30569640

Group type: EXPERIMENTAL
Intervention: Intermittent fasting at 70% energy requirements (IF70)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Intermittent fasting at 100% energy requirements (IF100)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Dietary restriction at 70% energy requirements (DR70)
Number of subjects: 88
Study: 27765481

Group type: EXPERIMENTAL
Intervention: HEART Pathway protocol
Number of subjects: 270

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 270
Study: 25592055

Group type: EXPERIMENTAL
Intervention: Developmentally Appropriate Symbols (DAS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Picture Communication Symbols (PCS)
Number of subjects: 40
Study: 23030240

Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD) with simplified papilla preservation flap (SPPF) technique
Number of subjects: 50

Group type: COMPARATOR
Intervention: Simplified papilla preservation flap (SPPF) alone
Number of subjects: 50
Study: 21453656

Group type: EXPERIMENTAL
Intervention: Budesonide-soaked Merocel MMS
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Manuka honey-soaked Merocel MMS
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nonmedicated Merocel MMS
Number of subjects: 48
Study: 19168520

Group type: EXPERIMENTAL
Intervention: Home-based walking and resistance exercise programme plus specialist nurse care
Number of subjects: 169

Group type: COMPARATOR
Intervention: Specialist nurse care alone
Number of subjects: 169
Study: 16460491

Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Albumin
Number of subjects: 40
Study: 15011975

Group type: EXPERIMENTAL
Intervention: Cooperative Learning (CL) activities
Number of subjects: 22

Group type: COMPARATOR
Intervention: Lecture
Number of subjects: 22
Study: 11354851

Group type: EXPERIMENTAL
Intervention: Postoperative brace for 6 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Nonbraced rehabilitation for 6 weeks
Number of subjects: 62
Study: 9207371

Group type: EXPERIMENTAL
Intervention: Itraconazole oral solution (100-200 mg once daily for 3-8 weeks)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Fluconazole tablets (100-200 mg once daily for 3-8 weeks)
Number of subjects: 126
Study: 7584265

Group type: EXPERIMENTAL
Intervention: Field perspective
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observer perspective
Number of subjects: 0
Study: 2950303

Group type: EXPERIMENTAL
Intervention: Intramuscular vaccine (20 micrograms)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intradermal vaccine (2 micrograms)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 30040009

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo Kinesio taping (placebo KT)
Number of subjects: 54
Study: 28476039

Group type: EXPERIMENTAL
Intervention: Nano-pulse stimulation (NPS) treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (surgery or no treatment)
Number of subjects: 24
Study: 25911162

Group type: EXPERIMENTAL
Intervention: Healthy sleep (10 hours in bed)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Sleep restriction (6.5 hours in bed)
Number of subjects: 67
Study: 23262114

Group type: EXPERIMENTAL
Intervention: Automated e-mails promoting evidence-based self-help strategies
Number of subjects: 568

Group type: COMPARATOR
Intervention: E-mails providing non-directive depression information (Control)
Number of subjects: 568
Study: 21491356

Group type: EXPERIMENTAL
Intervention: Expiratory muscle strength training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle strength training
Number of subjects: 0
Study: 19218826

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 0
Study: 16863044

Group type: EXPERIMENTAL
Intervention: 12-week, home-based, low- to moderate-intensity combined walking and education program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Education alone (control)
Number of subjects: 0
Study: 12514443

Group type: EXPERIMENTAL
Intervention: Patient-delivered partner treatment with azithromycin (dose not specified)
Number of subjects: 1787

Group type: COMPARATOR
Intervention: Self-referral (control group)
Number of subjects: 1787
Study: 14675583

Group type: EXPERIMENTAL
Intervention: Transient no-reflow during primary percutaneous coronary intervention
Number of subjects: 1192

Group type: COMPARATOR
Intervention: No transient no-reflow during primary percutaneous coronary intervention
Number of subjects: 1192
Study: 11016339

Group type: EXPERIMENTAL
Intervention: Reduction pneumoplasty (RP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comprehensive respiratory rehabilitation (RR)
Number of subjects: 60
Study: 8851740

Group type: EXPERIMENTAL
Intervention: Manipulated evaluation apprehension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manipulated self‐consciousness
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alcohol consumption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Broca's aphasics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wernicke's aphasics
Number of subjects: 0
Study: 1847363

Group type: EXPERIMENTAL
Intervention: Whole liver irradiation (33 Gy)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Whole liver irradiation (30 Gy) plus a boost of 15 Gy (6 patients) or 30 Gy (7 patients)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Concurrent use of intraarterial hepatic 5-fluorodeoxyuridine (FdUrd) as a radiosensitizer
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Hyperfractionation (1.5 Gy fractions given bid greater than 4 hr apart)
Number of subjects: 33
Study: 30848259

Group type: EXPERIMENTAL
Intervention: SPI‐7 (172 kcal sugar beverage with SPI at pH 7)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SPI‐6 (172 kcal sugar beverage with SPI at pH 6)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SPI + ALG‐7 (172 kcal sugar beverage with mixed SPI and alginate at pH 7)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SPI + ALG‐6 (172 kcal sugar beverage with mixed SPI and alginate at pH 6)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SPI + ALG‐6
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SPI + ALG‐7
Number of subjects: 12

Group type: COMPARATOR
Intervention: CONT (122 kcal sugar beverage)
Number of subjects: 12
Study: 29557854

Group type: EXPERIMENTAL
Intervention: Locally-tailored demand creation activities (mass media, community mobilization, targeted service delivery)
Number of subjects: 10217

Group type: COMPARATOR
Intervention: Control arms (no tailored demand creation)
Number of subjects: 10217

Group type: EXPERIMENTAL
Intervention: Locally-tailored demand creation activities
Number of subjects: 10217
Study: 26863234

Group type: EXPERIMENTAL
Intervention: l-citrulline
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: WBVT+l-citrulline
Number of subjects: 41

Group type: COMPARATOR
Intervention: WBVT+Placebo
Number of subjects: 41
Study: 24229467

Group type: EXPERIMENTAL
Intervention: Hydrothermally processed maize starch (HPMS)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Uncooked maize starch (UCMS)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Dextrose (DEX)
Number of subjects: 8
Study: 22828696

Group type: EXPERIMENTAL
Intervention: Thoracic interlaminar epidural injections with or without steroids
Number of subjects: 17
Study: 20429696

Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Pharmacological treatment (reference group)
Number of subjects: 153
Study: 17505569

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study: 16153514

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation in patients with atrial fibrillation and echocardiographic risk factors
Number of subjects: 173

Group type: COMPARATOR
Intervention: Control group (atrial fibrillation patients without echocardiographic risk factors)
Number of subjects: 173
Study: 11773086

Group type: EXPERIMENTAL
Intervention: Precore mutant ratios at baseline in group 1 (persistent high viremia and ALT elevation after anti-HBe seroconversion)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Precore mutant ratios at baseline in group 2 (remission)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Precore mutant ratios >50% at baseline
Number of subjects: 53

Group type: COMPARATOR
Intervention: Precore mutant ratios <50% at baseline
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Correlation of precore mutant ratios with ALT levels
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Correlation of intervals from presentation to anti-HBe seroconversion with ALT and precore mutant ratios
Number of subjects: 53
Study: 10549964

Group type: EXPERIMENTAL
Intervention: 150 mg intramuscular pethidine
Number of subjects: 133

Group type: COMPARATOR
Intervention: 7.5 mg intramuscular diamorphine
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: 100 mg intramuscular pethidine
Number of subjects: 133

Group type: COMPARATOR
Intervention: 5 mg intramuscular diamorphine
Number of subjects: 133
Study: 7796785

Group type: EXPERIMENTAL
Intervention: Low-fat milk
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fermented low-fat milk
Number of subjects: 9

Group type: COMPARATOR
Intervention: Lemonade (control)
Number of subjects: 9
Study: 2347416

Group type: EXPERIMENTAL
Intervention: Tamoxifen and nandrolone decanoate
Number of subjects: 51

Group type: COMPARATOR
Intervention: Tamoxifen alone (Control)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Tamoxifen and nandrolone decanoate (and Control)
Number of subjects: 51
Study: 367136

Group type: EXPERIMENTAL
Intervention: 20 mg of isosorbide dinitrate
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30381248

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (100 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: d-Amphetamine (40 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 26888874

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) administration of parenteral nutrition (n = 59)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Peripheral IV administration of parenteral nutrition (n = 61)
Number of subjects: 121
Study: 25462646

Group type: EXPERIMENTAL
Intervention: Multi-family group therapy (MFGT) intervention (six sessions)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 46
Study: 23562264

Group type: EXPERIMENTAL
Intervention: nalmefene 18 mg/day
Number of subjects: 718

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 718
Study: 21519049

Group type: EXPERIMENTAL
Intervention: Brachial plexus block (sympathectomy)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-blocked arm (control)
Number of subjects: 10
Study: 19230711

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 3114

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 3114
Study: 16203059

Group type: EXPERIMENTAL
Intervention: Single dose of pneumococcal conjugate vaccine (PCV)
Number of subjects: 0